AVEO Pharmaceuticals — Investor Presentation (February 2013)
29 slides from AVEO Pharmaceuticals's investor presentation, Feb 27, 2013
Slide 1: Company Overview
1EXHIBIT 99.1 Company Overview NASDAQ: AVEO FEBRUARY 27, 2013
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, are forward-looking statements. The words “anticipate,” “believe,” “estimate,”
Slide 3: Investment Thesis
Investment Thesis • Tivozanib in development for multiple cancer indications st – Successful TIVO-1 trial in 1 -line RCC – Target PDUFA date in July 2013 – World-class partnership with Astellas – BATON Phase 2 studies in CRC & BC • Human Response Platform ™ supporting discovery and clinical Founded:
Slide 4: Anticipated Approval of Tivozanib
Anticipated Approval of Tivozanib 4
Slide 5: Basic Criteria for Approval of New Anticancer Drug
Basic Criteria for Approval of New Anticancer Drug • Positive outcome in adequate and well-controlled trials – Phase 3 TIVO-1 trial: superiority over sorafenib on primary endpoint of PFS • Median PFS (mos): 11.9 vs 9.1 in ITT; 12.7 vs 9.1 in treatment-naïve subpopulation – Phase 2 randomized discont
Slide 6: Basic Criteria for Approval of New Anticancer Drug
Basic Criteria for Approval of New Anticancer Drug • Positive outcome in adequate and well-controlled trials – Phase 3 TIVO-1 trial: superiority over sorafenib on primary endpoint of PFS • Median PFS (mos): 11.9 vs 9.1 in ITT; 12.7 vs 9.1 in treatment-naïve subpopulation – Phase 2 randomized discont
Slide 7: Basic Criteria for Approval of New Anticancer Drug
Basic Criteria for Approval of New Anticancer Drug • Positive outcome in adequate and well-controlled trials – Phase 3 TIVO-1 trial: superiority over sorafenib on primary endpoint of PFS • Median PFS (mos): 11.9 vs 9.1 in ITT; 12.7 vs 9.1 in treatment-naïve subpopulation – Phase 2 randomized discont
Slide 8: Basic Criteria for Approval of New Anticancer Drug
Basic Criteria for Approval of New Anticancer Drug • Positive outcome in adequate and well-controlled trials – Phase 3 TIVO-1 trial: superiority over sorafenib on primary endpoint of PFS • Median PFS (mos): 11.9 vs 9.1 in ITT; 12.7 vs 9.1 in treatment-naïve subpopulation – Phase 2 randomized discont
Slide 9: Final Overall Survival Results in TIVO-1
Final Overall Survival Results in TIVO-1 • PFS is accepted registration endpoint in advanced RCC • OS is secondary endpoint in TIVO-1; results not statistically significant % of control arm pts crossed 0.4% 8.3% 15% 21% 28% 37% 43% 48% 53% 57% 59% 61% 67% 58% 100% over to tivozanib *Final OS analysi
Slide 10: Use of Next-Line Treatments
Use of Next-Line Treatments *Other includes radiotherapy, cytokine or other therapy 10
Slide 11: OS in Patients from North America/Western Europe: Pre-specified Subpopulation Analysis
OS in Patients from North America/Western Europe (n=40): Pre-specified Subpopulation Analysis 11
Slide 12: Regulatory Status of Tivozanib in Advanced RCC
Regulatory Status of Tivozanib in Advanced RCC • NDA accepted for filing November 2012 • ODAC review of tivozanib NDA scheduled for May 2, 2013 • Target PDUFA action date set for July 28, 2013 12
Slide 13: Addressing Medical Need in RCC
Addressing Medical Need in RCC 13
Slide 14: RCC is Large and Growing Market
RCC is Large and Growing Market Global RCC Sales Estimates for 12 Months Ending 9-30-12 $2,500 $2.2B • Global RCC sales grew 17% from MAT $1.9B $2,000 Sep11 to MAT Sep12 • US growth of 33% in same period $1,500 • Growth drivers include $1,000 • Expanded treatment options • Price increases (US) 500 •
Slide 15: Development of 1st-Line RCC Therapies
st Development of 1 -Line RCC Therapies 2005 2006 2007 2008 2009 2010 2011 2012 2013 No Targeted Targeted Therapies Approved: Focus on Efficacy Therapies Toxicities Impact Daily Living 1 • >50% of patients taking sorafenib experienced hand-foot syndrome 2 3 • >50% of patients taking sunitinib or paz
Slide 16: Patient Perspectives on Toxicities: Patient KCA Survey
Patient Perspectives on Toxicities: 272 Patient KCA Survey Patients report stomach problems, fatigue, mouth sores and hand-foot syndrome as most troublesome side effects Relative Importance for RCC Therapies (10=most important) 10 8 6 4 2 0 PFS Stomach Fatigue Mouth Sores Hand-Foot Problems Syndrome
Slide 17: Today, 1st-Line RCC Market in Flux: Efficacy
st Today, 1 -Line RCC Market in Flux st 2012 was transformational year for 1 -line RCC: EFFICACY 1 • TIVO-1 data demonstrate tivozanib is only agent with >1 yr of PFS in treatment-naïve patients and safety profile distinguished from other agents 2 • COMPARZ data showed pazopanib PFS non-inferior to
Slide 18: Today, 1st-Line RCC Market in Flux: Tolerability
st Today, 1 -Line RCC Market in Flux 2012 was transformational year for 1 st-line RCC: TOLERABILITY 1 • TIVO-1 data demonstrate low rates of dose reductions (12%) and interruptions (18%) with tivozanib • Safety profile distinguished from other agents 2 • COMPARZ data showed pazopanib PFS non-inferio
Slide 19: Future Focuses on Efficacy and Tolerability
Future Focuses on Efficacy and Tolerability COMPARZ PISCES 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 New Data: Targeted Therapies Approved: Focus on Efficacy Focus on Efficacy AND Tolerability • Patient tolerability • Safety profile • Minimal dose modifications • Convenient dose and regimen
Slide 20: Launch Plan in RCC
Launch Plan in RCC 20
Slide 21: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives • Customer targeting plan for launch Estimated Annual RCC RCC Decile Customers Total FTEs Patients per Customer 10 (10%) 16 86.4 3.8 9 (20%) 49 28.0 5.1 8 (30%) 83 17.0 5.2 7 (40%) 126 11.6 6.7 6 (50%) 181 8.2 8.8 Analysis supports ~80 Sales Reps 5 (60%) 260 5.8
Slide 22: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives • Customer targeting plan for launch • Optimize brand platform and positioning – Distinct global positioning and differentiated messaging for launch Selective inhibition of VEGFR 1,2,3 Efficacy: PFS >1 year in treatment -naïve patients Potent inhibition Safety: L
Slide 23: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives • Customer targeting plan for launch • Optimize brand platform and positioning – Distinct global positioning and differentiated messaging for launch • Increase awareness of clinical unmet needs in RCC – Highlight challenges of disease and emphasize importance of
Slide 24: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives 24
Slide 25: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives • Customer targeting plan for launch • Optimize brand platform and positioning – Distinct global positioning and differentiated messaging for launch • Increase awareness of clinical unmet needs in RCC – Highlight challenges of disease and emphasize importance of
Slide 26: Key Pre-Launch Commercial Objectives
Key Pre-Launch Commercial Objectives • Refine understanding of RCC marketplace and opportunity for tivozanib – Comprehensive advisory board and market research plan – Customer targeting plan for launch • Optimize brand platform and positioning – Distinct global positioning and differentiated messagi
Slide 27: Looking beyond RCC
Looking beyond RCC 27
Slide 28: Biomarker Driven Approach to Tivozanib Development
Biomarker Driven Approach to Tivozanib Development BATON: Biomarker Assessment of Tivozanib in ONcology st st • Phase 2 in 1 -line metastatic • Phase 2 in 1 -line in metastatic triple colorectal cancer (n=252) negative breast cancer (n=147) • Tivozanib + mFOLFOX6 • Tivozanib + paclitaxel vs placebo
Slide 29: AVEO Investment Thesis
AVEO Investment Thesis • Tivozanib approval anticipated in 2013 – ODAC panel to be held May 2, 2013 – Target PDUFA action date of July 28, 2013 – MAA led by Astellas; anticipated submission in 2H13 • BATON studies ongoing • Human Response Platform TM supporting development • Commercial rights to all
AVEO Pharmaceuticals — Investor Presentation (February 2013) on 6ix